"Although up to 30% of CIDP patients can go into remission off treatment, only about 10% can remain off treatment for 5 years," Lewis said. "Tapering treatments can be done but must be weighed ...

Emerging data suggest a possible genetic contributor to CIDP. In a recent study, patients with CIDP had a high frequency of perforin gene variations that impair the function of cytotoxic T and ...

CIDP significantly affects daily life, with many patients needing mobility aids and caregiver support, impacting employment and quality of life. A real-world survey showed 22% of CIDP patients ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

CIDP is often considered the chronic form of Guillain-Barré Syndrome and, as such, can be more problematic in that it lasts longer, causes more damage and is more difficult to recover from. CIDP ...

Upcoming data readouts include MG and CIDP results for the anti-FcRn franchise ... expectations for batoclimab results and six-month remission data for Graves’ disease. CEO Matt Gline noted ...